Cover Image

Challenges and risks of using GLP-1 antagonists in treating type 2 diabetes and obesity

Introduction: Ozempic (semaglutide) is a long-acting GLP-1 receptor agonist widely used to treat type II diabetes and obesity. Its mechanism of action includes stimulation of insulin secretion, inhibition of glucagon secretion, and delaying gastric emptying, which leads to lower blood glucose levels...

Full description

Saved in:
Bibliographic Details
Main Authors: Agnieszka Głuszczyk (Author), Jakub Plizga (Author), Aleksandra Makłowicz (Author), Ewelina Kopczyńska (Author), Angelika Szpulak (Author), Agata Frańczuk (Author), Michalina Grzelka (Author), Julia Głoskowska (Author), Katarzyna Kuleta (Author), Patrycja Karkos (Author)
Format: Book
Published: Nicolaus Copernicus University in Toruń, 2024-08-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items